Photo of Swarup  Kumar, MBBS

Swarup Kumar, MBBS

Assistant Clinical Professor of Medicine
NPI Number:
1629451497
Academic Office Location:
Neag Comprehensive Cancer Center
UConn Health
263 Farmington Avenue
Farmington, CT 06030-8072
Phone: 860-679-2100
Website(s):

Neag Comprehensive Cancer Center

  • Looking for a Physician?

    This faculty member is also
    a practicing physician at UConn Health.

    Learn more >
Education
DegreeInstitutionMajor
MBBSJawaharial Institute of Post Medical Education and ResearchBachelor of Medicine and Surgery

Post-Graduate Training
TrainingInstitutionSpecialty
ResidencySaint Vincent HospitalInternal Medicine
FellowshipUConn School of MedicineHematology/Oncology

Awards
Name of Award/HonorAwarding Organization
Teaching award for Excellence in EducationHematology and Medical Oncology Fellowship Program

Abstracts

  • A case of gamma heavy chain disease: a rare B-cell disorder with successful therapeutic response
    Jackson Clark, Ritika Vankina, Swarup Kumar 2022 Oct;
  • Blue toes and monoclonal protein: a rare presentation of monoclonal gammopathy of renal significance and a novel treatment approach
    Jackson Clark, Swarup Kumar 2022 Oct;
  • Deep learning identifies morphological changes in whole slide images of treatment-resistant TNBC
    Ali Foroughi Pour; Te-Chia Wu; Jan Martinek; Swarup Kumar; Tobias Anzeneder; Stephanie Torkler; Franziska Sommermeyer; Karolina Palucka; Jeffrey Chuang Cancer Research 2022 Feb;(82):P1-02-01
  • Mast Cell Leukemia after t(8,21)AML ; a challenge in diagnosis and treatment
    Lakshmi Kolandra, William Baker, Swarup Kumar, Meghana Singh, Adriana Kahn NNECOS annual meeting 2021 2021 Oct;
  • An evaluation of patient workflow in hematology clinics at a university hospital referred for the workup of monoclonal gammopathy of undetermined significance (MGUS)
    Swarup Kumar, Radhika B Kulkarni, Gonca Ozcan, Asha Tipirneni, Ritika Vankina, and W. Jeffrey Baker Journal of Clinical Oncology 2021 Oct;39(28):207-207
  • Kirk K, Hooper K, Vankina R, Kumar S. Assessing the Development of Myelodysplastic Syndromes in Patients with Plasma Cell Dyscrasias. Blood (2023) 142 (Supplement 1): 6499.
  • Kolandra L, Bahgat J, Bernstein E, Petricca L, Ibrahim O, Kumar S. Lung cancer screening in the prison population. JCO Oncol Pract 19, 2023 (suppl 11; abstr 114).
  • Kumar S, Clark J, Alvarez‑Soto A, El Warrak S, Kumar S, Braish J, Reddy A. A single‑center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM). Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-280
  • Kumar S, Hooper K, Clark J, Alvarez‑Soto A, Rounds A. Early outcomes and therapy modification strategies in multiple myeloma patients treated with teclistamab, CD3XBCMA BITE: a single center experience. Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-024
  • Kumar S, Kirk K, Hooper , Vankina R. A retrospective assessment of biologically relevant genomic perturbations and variants of unknown significance in a cohort of plasma cell disorder at our institution; a single center experience. Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-384.
  • Vankina R, Kirk K, Hooper K, Reddy A, Kumar S. Thrombotic significance in plasma cell disorders: do associated clonal hematopoiesis of indeterminate potential (CHIP) mutations increase the risk? Clinical Lymphoma, Myeloma & Leukemia, Vol. 23, No. S2, S1-S356, 2023. P-102

Case Reports

Title or AbstractTypeSponsor/EventDate/YearLocation
Management of Bone Disease in Multiple Myeloma - Intercity Endocrinology Grand RoundsTalk2023